RELATED PARTY TRANSACTIONS

9 Months Ended

Dec. 31, 2023

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 2 – RELATED PARTY TRANSACTIONS

DDL has a service agreement with Nemaura Pharma Limited (“Pharma”), an entity controlled by the Company’s President and Chief Executive officer, to provide development, manufacture, and regulatory approval process under Pharma’s ISO13485 accreditation. Pharma invoices DDL for these services on a cost-plus basis.

The table below provides a summary of activity between the Company and Pharma for the nine months ended December 31, 2023 and 2022.

	Nine Months Ended December 31, 2023 (unaudited)			Nine Months Ended December 31, 2022 (unaudited)
Due to (from) related parties at beginning of period	$	920,782		$	(101,297	)
Amounts invoiced by Pharma to DDL, NM and TCL, primarily relating to research and development expenses		4,211,705			2,833,546
Amounts invoiced by DDL to Pharma		—			(3,159	)
Amounts received from Pharma		—			4,452
Amounts paid by DDL to Pharma		(4,311,770	)		(2,789,939	)
Foreign exchange differences		(20,314	)		31,077
Due to (from) related parties at end of period	$	800,403		$	(25,320	)